tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

H.C. Wainwright positive on MannKind deal for scPharmaceuticals

H.C. Wainwright reiterates a Buy rating on MannKind (MNKD) with a $9 price target saying it views the scPharmaceuticals (SCPH) acquisition positively. MannKind shares will benefit from a more diversified revenue base and the company paid a “very reasonable” price to acquire scPharmaceuticals, the analyst tells investors in a research note.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1